Efficacy and safety of etanercept in moderate-to-severe asthma: A randomised, controlled trial

European Respiratory Journal

Volumn 37, Issue 6, 2011, Pages 1352-1359

  Holgate, S T ^a   Noonan, M ^c   Chanez, P ^g   Busse, W ^d   Dupont, L ^h   Pavord, I ^b   Hakulinen, A ⁱ   Paolozzi, L ^e   Wajdula, J ^e   Zang, C ^e   Nelson, H ^f   Raible, D ^e  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

^c Allergy Associates Research Center   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e PFIZER INC   (United States)

^f DEPARTMENT OF MEDICINE   (United States)

^g AIX MARSEILLE UNIVERSITY   (France)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Asthma; Etanercept; Forced expiratory volume

Indexed keywords

BECLOMETASONE; BUDESONIDE; ETANERCEPT; FLUTICASONE; METHACHOLINE; PLACEBO;

ACCIDENTAL INJURY; ADULT; AGED; ANAPHYLAXIS; ARTICLE; ASTHENIA; ASTHMA CONTROL QUESTIONNAIRE; BACKACHE; BRONCHITIS; CONTROLLED STUDY; COUGHING; CYSTITIS; DISEASE EXACERBATION; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL INFECTION; HEADACHE; HUMAN; HYPERTENSION; INFLUENZA; INJECTION SITE REACTION; LARYNGITIS; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MIGRAINE; MODERATE PERSISTENT ASTHMA; MULTICENTER STUDY; MYALGIA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NECK PAIN; PEAK EXPIRATORY FLOW; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROVOCATION TEST; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SEVERE PERSISTENT ASTHMA; SINUSITIS; THORAX PAIN; TOOTH INFECTION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VAGINITIS; WHEEZING;

ADOLESCENT; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOGLOBULIN G; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 79957987328     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00063510     Document Type: Article

References (41)

1. Moore WC, Peters SP. Severe asthma: an overview. J Allergy Clin Immunol 2006; 117: 487-494.
2. Holgate ST, Holloway J, Wilson S, et al. Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol 2006; 117: 496-506.
3. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-α in asthma. Am J Respir Crit Care Med 2006; 174: 753-762. (Pubitemid 44511656)
4. Steinke JW, Borish L. 3. Cytokines and chemokines. J Allergy Clin Immunol 2006; 117: S441-S445.
5. Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004; 23: 723-729. (Pubitemid 38618143)
6. Godard P, Chanez P, Siraudin L, et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 19: 61-67. (Pubitemid 34105569)
7. Serra-Batlles J, Plaza V, Morejon E, et al. Costs of asthma according to the degree of severity. Eur Respir J 2009; 12: 1322-1326.
8. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984.
9. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993.
10. Shah A, Church MK, Holgate ST. Tumour necrosis factor alpha: a potential mediator of asthma. Clin Exp Allergy 1995; 25: 1038-1044.
11. Ito T, Wang YH, Duramad O, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 2005; 202: 1213-1223. (Pubitemid 41586952)
12. Keatings VM, Jatakanon A, Worsdell YM, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542-548. (Pubitemid 27085799)
13. Obase Y, Shimoda T, Mitsuta K, et al. Correlation between airway hyperresponsiveness and airway inflammation in a young adult population: eosinophil, ECP, and cytokine levels in induced sputum. Ann Allergy Asthma Immunol 2001; 86: 304-310. (Pubitemid 32240215)
14. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFa) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60: 1012-1018. (Pubitemid 41705469)
15. Azevedo I, de Blic J, Dumarey CH, et al. Increased spontaneous release of tumour necrosis factor-α by alveolar macrophages from wheezy infants. Eur Respir J 1997; 10: 1767-1773. (Pubitemid 27368368)
16. Hallsworth MP, Soh CP, Lane SJ, et al. Selective enhancement of GM-CSF, TNF-α, IL-1β and IL-8 production by monocytes and macrophages of asthmatic subjects. Eur Respir J 1994; 7: 1096-1102. (Pubitemid 24187330)
17. Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factor-α increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 1995; 152: 76-80.
18. Thomas PS, Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 2002; 57: 774-778. (Pubitemid 34984975)
19. Casale TB, Costa JJ, Galli SJ. TNF alpha is important in human lung allergic reactions. Am J Respir Cell Mol Biol 1996; 15: 35-44. (Pubitemid 126439853)
20. Thomas PS. Tumour necrosis factor-α: the role of this multifunctional cytokine in asthma. Immunol Cell Biol 2001; 79: 132-140.
21. Vilcek J, Feldmann M. Historical review: cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci 2004; 25: 201-209. (Pubitemid 38519911)
22. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-259. (Pubitemid 29063266)
23. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor α in refractory asthma. N Engl J Med 2006; 354: 697-708. (Pubitemid 43247140)
24. Morjaria JB, Chauhan AJ, Babu KS, et al. The role of a soluble TNFα receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008; 63: 584-591. (Pubitemid 351969250)
25. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double0blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179: 549-558.
26. Chanez P, Wenzel SE, Anderson GP, et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol 2007; 119: 1337-1348.
27. National Heart, Lung and Blood Institute. Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. NIH Publication No 97-4051. Bethesda, NIH, 1997.
28. Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902-907. (Pubitemid 29519356)
29. Juniper EF, Buist AS, Cox FM, et al. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999; 115: 1265-1270. (Pubitemid 29230632)
30. Rouhani FN, Meitin CA, Kaler M, et al. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir Med 2005; 99: 1175-1182. (Pubitemid 41102656)
31. Quaedvlieg V, Henket M, Sele J, et al. Cytokine production from sputum cells in eosinophilic versus non-eosinophilic asthmatics. Clin Exp Immunol 2005; 143: 161-166.
32. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176: 1062-1071. (Pubitemid 350223751)
33. ten Brinke A, Zwinderman AH, Sterk PJ, et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164: 744-748.
34. Kaminska M, Foley S, Maghni K, et al. Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction. J Allergy Clin Immunol 2009; 124: 45-51.
35. Van Den Brande JM, Braat H, Van Den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria Tlymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-1785. (Pubitemid 36666774)
36. Mitoma H, Horiuchi T, Tsukamoto H. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-α. Gastroenterology 2004; 126: 934-935.
37. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008; 58: 1248-1257. (Pubitemid 351705913)
38. Van Der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006; 54: 1063-1074. (Pubitemid 43672919)
39. Van Der Heijde D, Da Silva JC, Dougados M, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 1572-1577. (Pubitemid 44799667)
40. Saad AA, Ashcroft DM, Watson KD, et al. Persistence with antitumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009; 11: R52.
41. Barrera MV, Habicheyn S, Mendiola MV, et al. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol 2008; 18: 683-687.